Product Description
Mechanisms of Action: 30S Ribosomal Subunit Inhibitor,Protein Synthesis Inhibitor,16S Ribosomal RNA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Bulgaria | Chile | China | Colombia | Czech | Dominican Republic | Germany | Hong Kong | India | Indonesia | Ireland | Italy | Korea | Latvia | Lithuania | Malaysia | Malta | Morocco | New Zealand | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Singapore | Slovakia | South Africa | Taiwan | Thailand | Turkey | Ukraine | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Julio Ramirez
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Colorectal Cancer|Tuberculosis, Multidrug-Resistant|Extensively Drug-Resistant Tuberculosis
Phase 1: Tuberculosis|Osteomyelitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BCH_PPK003 | N/A |
Recruiting |
Tuberculosis |
2026-10-01 |
|
| STREAM | P3 |
Completed |
Tuberculosis, Multidrug-Resistant |
2022-05-13 |
|
| NEXT | P3 |
Completed |
Tuberculosis, Multidrug-Resistant|Extensively Drug-Resistant Tuberculosis |
2020-12-31 |
|
| P1026s | N/A |
Completed |
HIV Infections |
2020-09-30 |